Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Phase I Study Evaluating Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AN4035 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations and Enriched for CEACAM5 Expression

NCT07686445 is registered in ClinicalTrials.gov with Adlai Nortye Biopharma Co., Ltd. as lead sponsor.

NCT NCT07686445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07686445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Phase I Study Evaluating Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AN4035 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations and Enriched for CEACAM5 Expression
Lead sponsor
Adlai Nortye Biopharma Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 23, 2026
Completion date
December 31, 2028
Enrollment
228 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ceacam5, ras mutation, solid tumor (phase i)